INmune Bio and Quantum Computing Inc. are combining clinical data from four trials with QCi’s Dirac-3S quantum optimization machine to explore new uses for XPro1595, an investigational Alzheimer’s treatment. This collaboration marks QCi’s first commercial customer within the pharmaceutical and biotechnology sectors, extending quantum computing beyond its traditional applications, INmune Bio says.
The companies will analyze datasets to identify diseases sharing biological traits with those XPro targets, prioritizing conditions where trials could be accelerated; as INmune Bio CEO David Moss states, “This collaboration allows us to examine patient populations and biomarkers most likely to predict responses by analyzing large data sets.”
XPro Targets Inflammation in Alzheimer’s and Rare Diseases
INmune Bio is analyzing its extensive clinical dataset on Alzheimer’s and other diseases, accumulated over years of work with its investigational treatment XPro, using quantum computing. will combine data from pre-clinical research through four clinical trials to uncover relationships that could lead to new treatment indications and biomarkers. QCi’s Dirac-3S quantum optimization machine will be central to this effort, comparing results with conventional statistical and machine-learning methods to determine where quantum computing offers the greatest analytical advantage.
“This is a great example of what practical quantum computing can look like today,” said Yuping Huang, Chairman and Chief Executive Officer of QCi. The program’s design will also establish a repeatable discovery process for INmune Bio, allowing them to apply quantum computing to additional datasets and potential disease indications in the future.
The initial focus will be on rare diseases, where smaller, faster trials and potential pediatric approvals, including Priority Review Vouchers, could accelerate development. “INmune Bio has a complex scientific problem and a substantial body of clinical and biological data. Our job is to bring new computing capabilities to that problem and see what we can learn,” Huang added.
The potential to refine treatment decisions and identify promising patient populations represents a step toward realizing the promise of quantum computing in pharmaceutical research and opens an important new market for QCi. The work is intended to determine where quantum optimization adds value to the analysis, and to establish a process for future applications.
We’ve built a large clinical dataset on Alzheimer’s and other diseases, backed by years of work with XPro.
David Moss, Chief Executive Officer of INmune Bio
See today’s quantum computing news on Quantum Zeitgeist for the latest breakthroughs in qubits, hardware, algorithms, and industry deals.
